NCT05484024View on ClinicalTrials.gov

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

588

Participants

Timeline

Start Date

August 6, 2022

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2030

Conditions

Rectal Neoplasms MalignantRadiotherapy

Interventions

DRUG

Sintilimab

PD-1 inhibitor

RADIATION

Short-course radiotherapy

Pelvic radiation

COMBINATION_PRODUCT

CAPOX/mFOLFOX

chemotherapy regimen

Trial Locations (2)

Unknown

Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen

All Listed Sponsors

lead

Chinese Academy of Medical Sciences

OTHER

NCT05484024 - Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter